Theravance Biopharma (NASDAQ:TBPH) is scheduled to announce Q2 earnings results on Tuesday, August 12th, after market close. The consensus EPS Estimate is -$0.13 (+61.8% Y/Y) and the consensus Revenue ...

Iron sucrose injection is an iron replacement product indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease.